提格环素和低血糖,什么时候以及如何?
Hakeam A Hakeam1,2, Khadija A Sarkhi3, Alla Iansavichene4
1Pharmaceutical Care Division, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
概括
提格环素可以导致严重的低血糖,即使在停止治疗后,尤其是在患有脏问题的患者中. 这种代谢不良影响需要临床意识,因为数据仍然有限.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
- 药物不良反应 药物不良反应
背景情况:
- 低血糖是与死亡率增加相关的关键不良事件.
- 作为一种广泛的抗生素,tigecycline很少与代谢障碍有关.
- 了解tigecycline诱导的低血糖症对于患者的安全至关重要.
研究的目的:
- 为了描述tigecycline治疗期间低血糖症的临床表现.
- 综合现有关于这种罕见不良影响的证据.
- 讨论与tigecycline相关的低血糖的潜在风险因素和机制.
主要方法:
- 进行了全面的三阶段文献搜索.
- 搜索的数据库包括CENTRAL,MEDLINE,Embase和FDA不良事件报告系统.
- 纳入标准集中在人体研究和英语报告上.
主要成果:
- 关于tigecycline相关低血糖的数据有限.
- 低血糖症可以在治疗期间随时发生,严重,并在停止后持续.
- 功能障碍可能会增加风险;糖尿病和非糖尿病患者可能出现低血糖症.
结论:
- 与tigecycline相关的低血糖是显著的,尽管不常见的不良影响.
- 临床医生应警在接受tigecycline的患者中出现低血糖.
- 需要进一步的研究来阐明确切的原因和管理策略.
更多相关视频
相关概念视频
Hypoglycemia and Glucagon
263
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
263
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Oral Hypoglycemic Agents: Biguanides and Glitazones
204
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
204
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
175
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
175
Dipeptidyl Peptidase 4 Inhibitors
187
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
187
Oral Hypoglycemic Agents: Sulfonylureas
209
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
209


